Fig. 1

The mechanisms of action of elotuzumab. Upper left, elotuzumab binds SLAMF7 on MM cells, and its Fc fragment is then bound by CD16 on NK cells, mediating ADCC. Upper right, elotuzumab binds SLAMF7 on NK cells, directly enhancing its cytotoxicity. Bottom right, elotuzumab binds SLAMF7 on MM cells, inhibiting its interaction with BMSCs. NK cell natural killer cell; MM cell multiple myeloma cell; BMSC bone marrow stromal cell; ADCC antibody-dependent cellular cytotoxicity